(Q36883658)

16 August 2017

1 reference

title

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors (English)

1 reference

16 August 2017

1 reference

1 reference

Elwyn Cabebe

1

1 reference

16 August 2017

Heather Wakelee

series ordinal

2

1 reference

16 August 2017

publication date

1 February 2007

1 reference

Current Treatment Options in Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

15-27

1 reference

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

16 August 2017

cites work

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer

1 reference

12 December 2020

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

1 reference

12 December 2020

The role of vascular endothelial growth factor in blood vessel formation

1 reference

12 December 2020

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

12 December 2020

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

12 December 2020

Anti-angiogenesis: new concept for therapy of solid tumors

1 reference

12 December 2020

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

12 December 2020

Cancer statistics, 2006

1 reference

12 December 2020

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

12 December 2020

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

BRAF and RAS mutations in human lung cancer and melanoma

1 reference

12 December 2020

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

1 reference

12 December 2020

Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

1 reference

12 December 2020

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

Antiangiogenic tumour therapy: will it work?

1 reference

12 December 2020

VEGF-receptor signal transduction

1 reference

12 December 2020

Vascular permeability factor (VPF, VEGF) in tumor biology

1 reference

12 December 2020

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models

1 reference

12 December 2020

The splice variants of vascular endothelial growth factor (VEGF) and their receptors

1 reference

12 December 2020

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

12 December 2020

Revisions in the International System for Staging Lung Cancer

1 reference

12 December 2020

Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo

1 reference

12 December 2020

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy

1 reference

12 December 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

12 December 2020

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

1 reference

12 December 2020

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

12 December 2020

An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

12 December 2020

10.1007/S11864-007-0022-4

Identifiers

DOI

1 reference

16 August 2017

1 reference